Business Wire

SISVEL-INTERNATIONAL

14.4.2020 14:27:08 CEST | Business Wire | Press release

Share
Sisvel Announces the Launch of its MIOTY LPWAN Licensing Program

Sisvel International S.A. (“Sisvel”) announced today the launch of its “MIOTY” Licensing Platform, a new joint patent licensing effort for the MIOTY technology. The platform has been launched with patents owned, or controlled by, Fraunhofer-Institute for Integrated Circuits IIS (“Fraunhofer IIS”) and Diehl Metering GmbH (“Diehl”).

Fraunhofer IIS and Diehl are working together under the brand name MIOTY in the area of wireless technology for low power wide area networks (“LPWAN”). MIOTY technology is based on the protocol family Telegram Splitting Ultra Narrow band (“TS-UNB”) of the ETSI standard TS 103 357 (“TS-UNB Specification”).

Sisvel is organizing this licensing platform to make MIOTY technology accessible on fair, reasonable, and non-discriminatory terms and conditions by offering a royalty-bearing, non-transferable, non-assignable, non-exclusive license, with no right to grant sublicenses, under patents essential to the TS-UNB Specification. In addition, Sisvel offers a license to patents complementary to MIOTY implementations.
Further information about the terms and conditions of Sisvel’s MIOTY licenses are available on Sisvel’s website https://www.sisvel.com/licensing-programs/wireless-communications/mioty/introduction . For more details you may contact Sisvel at the following e-mail address MIOTY@sisvel.com .

The MIOTY Licensing Platform remains open to additional patent owners with relevant patents. Thus, Sisvel invites all parties that have patents or patent applications they believe to be essential to the protocol family TS-UNB of the ETSI standard TS 103 357 to contact Sisvel and submit those patent(s) for an evaluation by the program’s designated, independent evaluators.

About Fraunhofer IIS
The Fraunhofer-Gesellschaft is the leading organization for applied research in Europe. Its research activities are conducted by 74 institutes and research units at locations throughout Germany. The Fraunhofer-Gesellschaft employs a staff of more than 28,000, who work with an annual re-search budget totaling more than 2.8 billion euros.
The Fraunhofer Institute for Integrated Circuits IIS is one of the world’s leading application-oriented research institutions for microelectronic and IT system solutions and services. It is the largest of all Fraunhofer Institutes. Research at Fraunhofer IIS revolves around two guiding topics:
In the area of “Audio and Media Technologies”, the institute has been shaping the digitalization of media for more than 30 years now. Fraunhofer IIS was instrumental in the development of mp3 and AAC and played a significant role in the digitalization of the cinema. Current developments are opening up whole new sound worlds and are being used in virtual reality, automotive sound systems, mobile telephony, streaming and broadcasting.
In the context of “cognitive sensor technologies”, the institute researches technologies for sensor technology, data transmission technology, data analysis methods and the exploitation of data as part of data-driven services and their accompanying business models. This adds a cognitive component to the function of the conventional “smart” sensor.
Nearly 1,100 employees conduct contract research for industry, the service sector and public authorities. Founded in 1985 in Erlangen, Fraunhofer IIS has now 15 locations in 11 cities: Erlangen (headquarters),
Nuremberg, Fürth, Dresden, further in Bamberg, Waischenfeld, Coburg, Würzburg, Ilmenau, Deggendorf and Passau. The budget of 170 million euros is mainly financed by projects. 26 percent of the budget is subsidized by federal and state funds.
Detailed information on: www.iis.fraunhofer.de/en

About Diehl Metering
Diehl Metering is a corporate division of the Diehl Group, headquartered in Nuremberg. With a total annual turnover of 3.75 billion euros, the technology company employs around 17,200 people worldwide. The corporate division Metering supplies solutions for the intelligent use of water, thermal energy, gas and electricity.
Diehl Metering provides smart metering solutions to utilities companies through the intelligent networking of various metering devices into larger data platforms. These solutions offer transparency for utilities and municipalities, and enable considerably increased efficiency in reading, billing and service processes. Diehl Metering’s customers are also able to benefit from real-time effects such as early recognition of leaks and the optimisation of distribution networks through intelligent information regarding prompt adjustment of the offer to suit actual needs.
With Diehl Metering utilities are already perfectly equipped for smart metering as an important component of smart city concepts. Thanks to more than 20 years of experience with the company’s own radio technology, Diehl Metering has at its disposal excellent expertise in communications within the Internet of Things. The MIOTY LPWAN technology has been developed jointly by Fraunhofer IIS and Diehl Metering.
For further information, please visit www.diehl.com/metering

About Sisvel
Sisvel is a world leader in fostering innovation and managing intellectual property. The Group identifies, evaluates and maximizes the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Founded in 1982, the Group is headquartered in Luxembourg and has subsidiaries in China, Germany, Italy, Japan, Spain, the United States and the United Kingdom. The Group has a long history of managing successful patent portfolios including those related to the audio compression standards known as MP3 and MPEG Audio, as well as broadcasting and receiving of digital terrestrial television standards maintained by the DVB Project. Sisvel currently operates patent pools and joint licensing programs in the fields of mobile communication; wireless local area networking 802.11; digital video broadcasting; recommendation engine and broadband access to data networks.
For additional information, please visit: www.sisvel.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye